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Abstract
Background: Disparities in cervical cancer incidence and mortality rates exist among women of
African ancestry (African-American, African-Caribbean and African). Persistent cervical infection
with Human papillomavirus (HPV) is associated with cervical dysplasia and if untreated, could
potentially progress to invasive cervical cancer. Very few studies have been conducted to examine
the true prevalence of HPV infection in this population. Comparisons of cervical HPV infection and
the type-specific distribution of HPV were performed between cancer-free Caribbean and US
women.
Results: The Caribbean population consisted of 212 women from Tobago and 99 women from
Jamaica. The US population tested, consisted of 82 women from Pittsburgh. The majority of the US
subjects was Caucasian, 74% (61/82) while 12% (10/82) and 13% (11/82) were African-American or
other ethnic groups, respectively. The age-adjusted prevalence of any HPV infection among women
from Tobago was 35%, while for Jamaica, it was 81% (p < 0.0001). The age-adjusted prevalence of
HPV infection for Caribbean subjects was not statistically significantly different from the US (any
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HPV: 47% vs. 39%, p > 0.1; high-risk HPVs: 27% vs. 25%, p > 0.1); no difference was observed
between US-Blacks and Jamaicans (any HPV: 92% vs. 81%, p > 0.1; high-risk HPV: 50% vs. 53%, p >
0.1). However, US-Whites had a lower age-adjusted prevalence of HPV infections compared to
Jamaican subjects (any HPV: 29% vs. 81%, p < 0.0001; high-risk HPV: 20% vs. 53%, p < 0.001).
Subjects from Jamaica, Tobago, and US-Blacks had a higher proportion of high-risk HPV infections
(Tobago: 20%, Jamaica: 58%, US-Blacks: 40%) compared to US-Whites (15%). Similar observations
were made for the presence of infections with multiple high-risk HPV types (Tobago: 12%, Jamaica:
43%, US-Blacks: 30%, US-Whites: 8%). Although we observed similar prevalence of HPV16
infections among Caribbean and US-White women, there was a distinct distribution of high-risk
HPV types when comparisons were made between the ethnic groups.
Conclusion: The higher prevalence of cervical HPV infections and multiple high-risk infections in
Caribbean and US-Black women may contribute to the high incidence and prevalence of cervical
cancer in these populations. Evaluation of a larger sample size is currently ongoing to confirm the
distinct distribution of HPV types between ethnic groups.
Background
Disparities in cervical cancer incidence and mortality rates
exist among all women of African ancestry (African-Amer-
ican, African-Caribbean and African) [1,2]. The world
standardized age-adjusted incidence and mortality rates
per 100,000 for African-American women are 8.6 and 3.4,
respectively vs. 6.7 and 1.7 for Caucasians in the United
States (US) [1]. Furthermore, African and Caribbean
countries have the top two highest incidence and mortal-
ity rates, above Asia, the Americas and Europe [2].
Almost all cases of invasive cancers of the cervix, most
other anogenital tract cancers [3], and approximately 36%
of oropharyngeal cancers [4], are associated with HPV
infection. In addition to persistent HPV infection with
high-risk genotypes, access to screening as well as behav-
iors such as early age of sexual intercourse, multiple sex
partners, and lifetime number of partners are risk factors
associated with the development of cervical cancer.
Although the HPV infection rate is high in the Caribbean
[5], very few studies have been conducted to measure the
true prevalence of HPV infection in this population. In
addition, there are not enough data that describe the dis-
tribution of HPV types among cancer cases and healthy
controls from the many islands throughout the Carib-
bean. Since the HPV vaccine specifically prevents cancers
caused by HPV16 and 18, knowledge of the HPV type dis-
tribution in these populations is important in order to
evaluate the impact of the current HPV vaccine on these
at-risk populations.
We have previously reported the HPV type distribution in
two cancer-free Caribbean populations, Jamaica [6] and
Tobago [7]. In this study, we have compared the preva-
lence and genotype distribution of cervical HPV infections
in these two Caribbean populations with that of US
women.
Methods
Study population
The Caribbean populations consisted of 212 women from
Tobago [6] and 99 women from Jamaica [7]. The US pop-
ulation consisted of 88 women from Pittsburgh. All of the
subjects from the three geographic areas were recruited
from the general population and none were pregnant. The
women from Tobago were recruited between July and
September 2004 by means of posters, flyers, public service
announcements on television and radio, word of mouth,
and a series of cancer information sessions conducted
throughout the island. The Jamaican women were
recruited during visits to a family practice in Western
Jamaica between January 2003 and October 2006. All
Jamaican participants were recruited consecutively to
avoid selection bias. The US study population was
enrolled from May 2007–Aug 2008 as part of a nested
cross-sectional study of the Epidemiologic STudy of
HEalth Risk (ESTHER) project, (an ongoing women's
study at the University of Pittsburgh). The ESTHER
project's sample recruitment methodology attempted to
address some of the biases related to use of a sample of
convenience. The targeted recruitment for ESTHER was
based on age, level of education, and race/ethnicity popu-
lation distributions. Recruitment strategies included
attending women focused events, news items and adver-
tisements in women-focused news sources, and limited
respondent driven sampling.
All subjects from Jamaica and Tobago combined are
referred to in this study as Caribbean. The majority of sub-
jects were African-Caribbean, although in Tobago, there
were 19 subjects who defined their ethnicity as East
Indian. The self-reported ethnic groups in the US popula-
tion were classified as White, Black or other ethnic groups.
One subject did not define her ethnicity and was included
in the other ethnic group category.Infectious Agents and Cancer 2009, 4(Suppl 1):S9 http://www.infectagentscancer.com/content/4/S1/S9
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HPV testing
Standardized protocols were implemented for sample col-
lection, DNA extraction and HPV testing for all three sub-
populations that were included in this analysis. A nurse or
clinician collected cervical brush samples and the DNA
was extracted from these samples using the Puregene DNA
purification kit (Qiagen, Germantown, MD, USA). The
HPV genotyping was performed on these samples using
the Linear Array HPV Genotyping kit (Roche Diagnostics).
All cervical samples were tested at the University of Pitts-
burgh. The assay involved amplification of samples by
PCR using a master mix which contained biotin-labeled
primers for the detection of the 37 most common HPV
genotypes as well as the human beta-globin gene. The
PCR products were chemically denatured and hybridized
for 30 min at 53°C to linear array strips which contained
specific and one cross-reactive oligonucleotide probe for
the HPV genotypes as well as a high and low concentra-
tion of a beta-globin probe. The HPV genotypes were
identified when visualized using a streptavidin-horserad-
ish peroxidase conjugate and a substrate solution contain-
ing hydrogen peroxide and 3,3',5,5'-tetramethylbenzidine
which yielded a blue precipitate at the positions where the
hybridization occurred.
For six samples from the US population, beta-globin was
not positive, which indicated either poor quality or low
yield DNA samples. These samples were excluded. There-
fore, HPV results were available for only 82 US samples.
All of the samples from Jamaica were tested with the
AMPLICOR HPV method [7] prior to testing with the Lin-
ear Array HPV Genotyping kit. Ten samples from the
Jamaican population tested HPV-negative using our assay,
possibly due to a lower sensitivity. Therefore, for our
study, these samples were classified as HPV X.
The Linear Array protocol does not specifically detect
HPV52. The cross-reactive probe in this assay detects HPV
33, 35, 52 and 58 combined. According to the manufac-
turer's protocol, samples that are negative for HPV 33, 35,
and 58 individually, but positive for the cross-reactive
probe are classified as HPV 52-positive. Samples that are
positive for HPV 33, 35, and/or 58 individually, as well as
the cross-reactive probe have an uncertain HPV 52 status.
For our study these samples were considered negative for
HPV 52.
HPV-risk classification was based on the epidemiological
classification of HPV types that are associated with cervi-
cal cancer [8]. Briefly there are fifteen high-risk HPV types:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82;
three probable high-risk HPV types: 26, 53, 66 and twelve
low-risk HPV types: 6, 11, 40, 42, 43, 44, 54, 61, 70, 72,
81, CP6108. For this analysis, we combined probable
high-risk HPV types and high-risk HPV types into a single
group. The HPV types that do not fall into any of these
aforementioned categories were classified as undeter-
mined risk.
Statistical analysis
All statistical analyses were performed using STATA SE
(version 10), (StataCorp LP, College Station, TX). Age-
adjusted prevalence rates and confidence intervals were
calculated using logistic regression estimates of infection
with any HPV type or any high-risk HPV type, adjusted for
age. Observations with missing values of age were
dropped from the analysis before estimation. The chi-
squared test of proportions was used to calculate p-values
for the unadjusted differences in proportions as well as, p-
values for the differences in adjusted proportions.
Although age and age at first sexual intercourse were both
normally distributed, we rejected the hypothesis of equal
variances. Therefore, the comparisons of mean age and
age at first sexual intercourse were performed using two-
sample t-tests on the equality of means adjusting for une-
qual variances.
Table 1: Characteristics of the study population.
Tobago Jamaica US Total
Number of subjects 212 99 82 393
Population source GP GP GP GP
Age (years, mean ± SD) 41 ± 11.6 36 ± 11.7
(n = 91)
53 ± 9.0 42 ± 12.7
(n = 391)
Age, first sexual intercourse
(years, mean ± SD)
18 ± 3.5
(n = 191)
17 ± 2.8
(n = 95)
19 ± 3.8
(n = 80)
18 ± 3.5
(n = 366)
Number of sex partners N (%)
1–5 153 (79.7) 72 (74.2) 48 (60.8) 273 (74.2)
6–15 39 (20.3) 20 (20.6) 24 (30.4) 83 (22.6)
16+ 0 (0.0) 5 (5.2) 7 (8.9) 12 (3.3)
GP = general population; SD = standard deviation; when there are subjects with missing data, the number of the subpopulation (n) used to calculate 
the overall means is indicated in each cell.Infectious Agents and Cancer 2009, 4(Suppl 1):S9 http://www.infectagentscancer.com/content/4/S1/S9
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Results
Study populations
Table 1 summarizes the characteristics of each subpopula-
tion. The overall study population consisted of 393 sub-
jects (mean age 42 ± 12.7 years) who were recruited from
the general population. The Caribbean subjects consisted
of 212 women from Tobago [6] (mean age: 41 ± 11.6
years). The 99 women from Jamaica [7] (mean age: 36 ±
11.7 years) were the youngest population, while the US
population, which consisted of 82 women (mean age: 53
± 9.0 years) was the oldest (p < 0.0001). The majority of
subjects in the US population were White, 76% (67/88),
while 11% (10/88) and 13% (11/88) were African-Amer-
ican or other ethnic groups, respectively.
The mean age at first sexual intercourse for each subpop-
ulation ranged from 17 to 19 years old, with an overall
mean of 18 ± 3.5 years. The age at first sexual intercourse
for Jamaican women was statistically significantly
younger than women from Tobago (Jamaica: 17 ± 2.8
years vs. Tobago: 18 ± 3.5 years, p = 0.01) and US women
(vs. US: 19 ± 3.8 years, p = 0.0001).
Comparisons of cervical HPV prevalence between 
countries
Thirty-five percent (75/212) of the women from Tobago,
84% (83/99) of the women from Jamaica and 32% (26/
82) of US women, tested positive for HPV infection of any
HPV type. Table 2 summarizes the age-adjusted preva-
lence of HPV infections in our study population.
Although the age-adjusted prevalence rate of any HPV
infection was higher overall in the Caribbean (47%), it
was not significantly different from the United States
(39%, p = 0.281). Similar observations were made when
only high-risk HPV infections were considered (Carib-
bean: 27%, US 25%, p = 0.758). The highest prevalence of
high-risk HPV infections was observed in Jamaican
women (age-adjusted prevalence = 53%), while women
from Tobago had a statistically significantly lower age-
adjusted prevalence of high-risk HPV infections (18%, p <
0.0001). Statistically significant differences were observed
between the age-adjusted prevalence of high-risk HPV
infections among US Whites (20%) and Jamaican women
(p = 0.001). In contrast, there was no statistically signifi-
cant difference in the prevalence of high-risk infections
among US-Blacks (50%) when compared to Jamaican
subjects (p > 0.1).
Geographical distribution of high-risk HPV types and 
multiple high-risk HPV infections
Figure 1 summarizes the HPV type distribution of high-
risk HPV infections among all women infected with high-
risk HPV types. In both Caribbean islands, HPV 45 (over-
all: 26%, Tobago: 19% and Jamaica: 31%) rather than
HPV 16 (overall: 13%, Tobago: 12% and Jamaica 14%) or
HPV 18 (overall: 14%, Tobago: 5% and Jamaica: 21%)
was the most common high-risk genotype detected. In
contrast, US women had a different distribution of high-
risk genotypes. HPV 33 infections were highest among the
high-risk types in this population (overall: 29%, US-
Blacks: 25%, US-Whites: 22%) rather than HPV 16 (over-
all: 7%, US-Blacks: 0%, US-Whites: 11%) or HPV 18
(overall: 7%, US-Blacks: 0%, US-Whites: 11%). Neverthe-
less, although not statistically significant, we observed a
higher prevalence rate of HPV 16 and 18 infections among
Caribbean subjects that were infected with high-risk HPV
types when compared to the US women (HPV 16: 13% vs.
7%, p > 0.1 and HPV 18: 14% vs. 7%, p > 0.1).
The proportion of high-risk HPV infections appears to be
highest among women of African ancestry. Jamaican
women had the highest proportion of high-risk HPV
infections (58.6%), then US-Black (40%), Tobago
(20.3%) and US White (14.5%) women, followed by
women from the US-other group (10%), (Table 3). Fifty
percent of US-black women, 40.4% of Jamaican women,
23.1% of Tobago women, 16.1% of US-white (40.4%)
and 10% of women from the US-other group had single
high-risk HPV infections. Similar observations were made
for multiple high-risk HPV infections, US-whites and US-
Table 2: Prevalence of HPV infection by geographic location.
Country Test method Age-adjusted 
prevalence any 
HPV (%), 95% CI
p-value, Country p-value, Ethnic 
group
Age-Adjusted 
prevalence high-
risk HPV (%), 
95% CI
p-value, Country p-value, Ethnic 
group
Caribbean PCR 47.1 (41.3–53.0) ref 27.4 (22.3–33.3) ref
Jamaica 80.5 (70.5–87.8) ref 52.7 (41.4–63.6) ref
Tobago 34.5 (28.3–41.2) <0.0001 18.3 (13.5–24.2) <0.0001
United States PCR 39.4 (28.2–51.8) 0.281 25.3 (15.5–38.4) 0.758
US-Blacks 91.8 (58.3–98.9) 0.368 49.7 (21.4–78.2) 0.867
US-Whites 29.0 (18.0–43.0) <0.0001 20.2 (10.9–34.7) 0.001
US-Other 22.9 (5.9–58.5) 0.002 16.0 (2.3–61.0) 0.111
p-values for the differences in adjusted proportions.Infectious Agents and Cancer 2009, 4(Suppl 1):S9 http://www.infectagentscancer.com/content/4/S1/S9
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other had lower proportions (8.1% and 10%, respec-
tively). Higher proportions of multiple infections were
observed among Jamaicans (43.4%), US-blacks (30%)
and women from Tobago (12.3%). In general, multiple
high risk infections among Caribbean women ranged
from 2–6 high-risk HPV types whereas no more than two
high-risk HPV types were detected among US Blacks.
Discussion
This is the first study to report comparisons of the preva-
lence of cervical HPV infections and the specific HPV gen-
otypes between cancer-free Caribbean and US women. We
have shown that the age-adjusted prevalence rate of any
HPV infection was higher in the Caribbean women (47%)
than in women from the United States (39%), although
the age-adjusted prevalence of high-risk HPV infections
(Caribbean 27%, US 25%) was similar in both popula-
tions. The inability to achieve statistical significance for
high-risk HPV infections may be related to the small sam-
ple size of the US population and consequently insuffi-
cient statistical power to detect a difference between the
two groups. Nevertheless, our findings suggest that the
higher rates of HPV infection in the Caribbean compared
to the US, are likely to explain the higher incidence of cer-
vical cancer reported in the region [2].
The distribution of HPV types was similar in the two Car-
ibbean islands but was different from that observed in the
US. This is not unexpected, since differences in the geo-
graphical distribution of HPV infections have previously
been reported [9]. We observed that HPV 16 and 18 were
not the predominant high-risk genotypes detected in can-
cer-free Caribbean women. Our results show that Carib-
bean women have a higher proportion of HPV 45
infections, the third most common high-risk HPV geno-
type that drives cervical carcinogenesis [8,10]. Studies are
currently ongoing to determine whether HPV 45 infec-
tions might be driving cervical cancer development in the
Caribbean region.
The current HPV vaccine prevents infections from HPV
types 6, 11, 16 and 18 [11]. The low-risk genotypes, HPV
6 and 11, are responsible for the development of genital
warts, while HPV 16 and 18 are the two most common
high-risk genotypes and are reported to account for
almost 70% of cervical cancers worldwide [10]. We
observed that HPV 16 and 18 infections are not seen in
high proportions among cancer-free Caribbean women.
However, Caribbean women still have a higher propor-
tion of HPV 16 and 18 infections compared to their US
counterparts (HPV 16: 13% vs. 7%, and HPV 18: 14% vs.
7%). These observed differences between the US and Car-
Distribution of high-risk HPV types among Caribbean and US  women with high-risk HPV infections Figure 1
Distribution of high-risk HPV types among Caribbean and US 
women with high-risk HPV infections.
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Table 3: Characteristics of HPV infections according to ethnicity.
Tobago N N (%) Jamaica N (%) US-Black N (%) US-White N (%) US-other N (%) Total
N (%)
Number of subjects 212 99 10 67 11 393
High-risk HPV infection 43 (20.3) 58 (58.6) 4 (40.0) 9 (14.5) 1 (10.0) 115 (29.3)
Low-risk HPV infection 15 (7.1) 25 (25.3) 4 (40.0) 4 (6.5) 1 (10.0) 49 (12.5)
Undetermined-risk infection 16 (7.6) 47 (47.5) 5 (50.0) 5 (8.1) 1 (10.0) 74 (18.3)
Single high-risk infection* 49 (23.1) 40 (40.4) 5 (50.0) 10 (16.1) 1 (10.0) 105 (26.7)
Multiple high-risk infection 26 (12.3) 43 (43.4) 3 (30.0) 5 (8.1) 1 (10.0) 78 (19.9)
Number of high-risk HPV types per subject
None** 169 (79.7) 41 (41.4) 6 (60.0) 53 (85.5) 9 (90.0) 278 (70.7)
1 33 (15.6) 34 (34.3) 3 (30.0) 7 (11.3) 1 (10.0) 78 (19.9)
2 7 (3.3) 11 (11.1) 1 (10.0) 2 (3.2) 0 (0.0) 21 (5.3)
3 2 (0.9) 7 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 9 (2.3)
4 1 (0.5) 2 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8)
5 0 (0.0) 3 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8)
6 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
*Includes subjects infected with low-risk and undetermined-risk HPV types; **Includes subjects that were HPV-negative or had only low-risk HPV 
infections.Infectious Agents and Cancer 2009, 4(Suppl 1):S9 http://www.infectagentscancer.com/content/4/S1/S9
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ibbean may be due to immune resistance to HPV16 and
18 genotypes in the US population (although we do not
have data to support these hypotheses). The evaluation of
serological status for HPV 16 and 18 and how these com-
pare to the prevalence of high-risk HPV infections in both
geographical regions are needed in order to test these
hypotheses. Nevertheless, the higher incidence of cervical
cancers in the Caribbean region compared to the US
might be attributed to the higher proportions of HPV 16
and 18 infections observed in the Caribbean.
Caribbean and US-Black subjects in comparison with US-
Whites have higher prevalence rates of high-risk HPV
infections and also a higher proportion of subjects with
multiple-high-risk HPV infections. This may be related to
sexual behaviour, social class (poverty and malnutrition),
high parity, lack of barrier contraceptive protection and
use of steroidal contraception, [7,12-16]. However, these
confounders could not be assessed in our study because
these data were not available. Furthermore, the risk of cer-
vical cancer among women with multiple high-risk infec-
tions has not been well studied; therefore additional
studies are warranted.
Studies show that younger age is associated with an
increased risk of cervical HPV infection [17-20]. There-
fore, for comparisons of HPV infections between different
populations, age must be standardized. A limitation in
our study is that although all subjects were recruited from
the general population, the mean age for each country was
different. Pittsburgh subjects were the oldest (mean age =
53 ± 9.0 years), and this was representative of the older
population in the geographical region [21]. Jamaican
women were the youngest population, also reflecting the
demographics for the country [22]. To address this limita-
tion, we have presented age-adjusted prevalence rates so
that these values might be compared. Another limitation
in this study is that only 11% (N = 10) of the US study
population were African-American, which did not allow
for adequate comparisons between African-American and
Caribbean women. However, the proportion of African-
American subjects is representative of the Pittsburgh
demographics.
Conclusion
The higher prevalence of cervical HPV infections and mul-
tiple high-risk infections in Caribbean and US-Black
women may contribute to the high incidence and preva-
lence of cervical cancer in these populations. Further stud-
ies of the distribution of HPV types between ethnic groups
and the risk of cervical cancer among women with multi-
ple high-risk infections are currently ongoing.
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